Latest Regulatory Approvals News

Moho Resources advances its gold exploration in Western Australia with significant tenement grants and high-grade surface samples at Bush Chook, alongside promising soil anomalies at Silver Swan North. Maiden drilling is planned for late 2025, marking a pivotal step in unlocking project potential.

NexGen Energy Ltd. has launched a significant dual equity financing, successfully upsizing its Australian offering and targeting combined proceeds exceeding C$1 billion. This move underscores the company's strategic capital expansion across North American and Australian markets.

Duxton Farms has successfully passed all scheme resolutions required to advance its strategic acquisition of four Australian private companies in walnuts, dried fruits, orchards, and bees. The merger awaits final conditions before completion.

Centaurus Metals has secured the final mining lease for its Jaguar Nickel Project in Brazil, clearing a major regulatory hurdle and moving closer to a Final Investment Decision and project development.

Trigg Minerals is advancing its strategy to list on the U.S. NASDAQ, weighing options including a dual listing and potential SPAC mergers, while planning a name change to reflect its evolving focus.

Toubani Resources has locked in a comprehensive A$395 million funding package, fully financing the development of its Kobada Gold Project in Mali and positioning itself as a future high-margin West African gold producer.

Toubani Resources has locked in a transformative A$395 million funding package to advance its Kobada Gold Project in Mali, setting the stage for production to commence by the third quarter of 2027.

NSX Limited shareholders overwhelmingly approved a scheme of arrangement for acquisition by 1001290557 Ontario Inc., a related entity of the Canadian Stock Exchange operator CNSX Markets Inc. The deal, valued at four cents per fully paid share, now awaits Federal Court approval to proceed.

Kingsgate Consolidated updates its 2025 Mineral Resources and Ore Reserves, introducing a maiden estimate for the Chatree South-East Complex while reporting modest declines in overall Ore Reserves.

Prescient Therapeutics has bolstered its cash reserves to $12.3 million following a $9.8 million capital raise, while progressing its PTX-100 cancer therapy through global Phase 2 trials with encouraging early lymphoma results.

Medical Developments International reported a strong start to FY26 with significant revenue growth driven by increased Penthrox volumes and pricing improvements in Australia, alongside steady European demand and progress on paediatric label approvals.

Orthocell Limited has reported a record $3 million quarterly revenue, driven by strong sales of its nerve repair product Remplir in Australia and Singapore, while advancing its rollout in the US and Canada ahead of schedule.